Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 7/20 | 0.62 |
| ▸ | ROCK1 | Q13464 | 7/20 | 0.62 |
| ▸ | MAPT | P10636 | 5/20 | 0.60 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.59 |
| ▸ | GSTO1 | P78417 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.57 |
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.57 |
| ▸ | RAB9A | P51151 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 5/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.57 |
| ▸ | STAT3 | P40763 | 1/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.57 |
| ▸ | ELOVL1 | Q9BW60 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29276746 | 0.88 | LMNA (0.58) | ROCK2ROCK1MAPTLMNARAB9A | |
| SCHEMBL2752589 | 0.87 | LMNA (0.68) | ROCK2ROCK1MAPTADORA3GSTO1 | |
| SCHEMBL2753326 | 0.87 | ROCK2 (0.60) | ROCK2ROCK1MAPTADORA3GSTO1 | |
| SCHEMBL10954503 | 0.85 | MAPT (0.61) | ROCK2ROCK1MAPTADORA3GSTO1 | |
| SCHEMBL21224203 | 0.85 | XIAP (0.65) | ROCK2ROCK1MAPTADORA3GSTO1 | |
| SCHEMBL21224205 | 0.85 | XIAP (0.65) | ROCK2ROCK1MAPTADORA3GSTO1 | |
| SCHEMBL10957280 | 0.85 | MAPT (0.61) | ROCK2ROCK1MAPTADORA3GSTO1 | |
| SCHEMBL21224175 | 0.84 | MEN1 (0.60) | ROCK2ROCK1MAPTADORA3GSTO1 | |
| Hydrochloric Acid SCHEMBL28527539 | 0.84 | XIAP (0.63) | ROCK2ROCK1MAPTADORA3GSTO1 | |
| Hydrochloric Acid SCHEMBL28527541 | 0.84 | XIAP (0.63) | ROCK2ROCK1MAPTADORA3GSTO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160228414-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED | 2016-08-11 | — | — | US | disclosed |
| US-20160228414-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED | 2016-08-11 | — | — | US | disclosed |
| US-9249131-B2 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2016-02-02 | — | — | US | disclosed |
| US-9249131-B2 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2016-02-02 | — | — | US | disclosed |
| US-20150025076-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED | 2015-01-22 | — | — | US | disclosed |
| US-20150025076-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED | 2015-01-22 | — | — | US | disclosed |
| US-8853415-B2 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-10-07 | — | — | US | disclosed |
| US-8853415-B2 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-10-07 | — | — | US | disclosed |
| US-8741939-B2 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-06-03 | — | — | US | disclosed |
| US-8741939-B2 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-06-03 | — | — | US | disclosed |
| US-20140072995-A1 | Modulators of ATP-Binding Cassette Transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-03-13 | — | — | US | disclosed |
| US-20140072995-A1 | Modulators of ATP-Binding Cassette Transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-03-13 | — | — | US | disclosed |
| US-8431605-B2 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICAL INCORPORATED (US) | 2013-04-30 | — | — | US | disclosed |
| US-8431605-B2 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICAL INCORPORATED (US) | 2013-04-30 | — | — | US | disclosed |
| US-20120004216-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-01-05 | — | — | US | disclosed |
| US-20120004216-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-01-05 | — | — | US | disclosed |
| US-7973169-B2 | including cystic fibrosis transmembrane conductance regulator (\"CFTR\"), such as N-(4,5-Diphenyl-thiazol-2-yl)-benzamide, used for treating genetic disorders; respiratory system disorders | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-07-05 | — | — | US | disclosed |
| US-7973169-B2 | including cystic fibrosis transmembrane conductance regulator (\"CFTR\"), such as N-(4,5-Diphenyl-thiazol-2-yl)-benzamide, used for treating genetic disorders; respiratory system disorders | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160228414-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | CFTR, ABCB1, ABCF1 | ROCK2 4094/4885ROCK1 4299/4885MAPT 4106/4885 |
| US-20120004216-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | CFTR, ABCB1, ABCF1 | ROCK2 4094/4885ROCK1 4299/4885MAPT 4106/4885 |
| US-20150025076-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | CFTR, ABCB1, ABCF1 | ROCK2 4061/4885ROCK1 4257/4885MAPT 4100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.